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Background: Translocation of high-mobility group box 1 (HMGB1) from nucleus could trigger inflammation.
Extracellular HMGB1 up-regulates inflammatory response in sepsis as a late mediator. However, little was known
about its role in subarachnoid hemorrhage-inducible inflammation, especially in the early stage. This study aims to
identify whether HMGB1 translocation occurred early after SAH and also to clarify the potential role of HMGB1 in
brain injury following SAH.
Methods: Sprague-Dawley (SD) rats were randomly divided into sham group and SAH groups at 2 h, 12 h and on
day 1, day 2. SAH groups suffered experimental subarachnoid hemorrhage by injection of 0.3 ml autoblood into the
pre-chiasmatic cistern. Rats injected by recombinant HMGB1(rHMGB1) solution were divided into four groups
according to different time points. Cultured neurons were assigned into control group and four hemoglobin (Hb)
incubated groups. Mixed glial cells were cultured and stimulated in medium from neurons incubated by Hb. HMGB1
expression is measured by western blot analysis, real-time polymerase chain reaction (PCR), immunohistochemistry and
immunofluorescence. Downstream nuclear factor kappa B (NF-κB) subunit P65 and inflammatory factor Interleukin 1β
(IL-1β) were measured by western blot and real-time PCR, respectively. Brain injury was evaluated by cleaved caspase-3
staining.
Results: Our results demonstrated HMGB1 translocation occurred as early as 2 h after experimental SAH with mRNA
and protein level increased. Immunohistochemistry and immunofluorescence results indicated cytosolic HMGB1 was
mainly located in neurons while translocated HMGB1 could also be found in some microglia. After subarachnoid
injection of rHMGB1, NF-κB, downstream inflammatory response and cleaved caspase-3 were up-regulated in the
cortex compared to the saline control group. In-vitro, after Hb incubation, HMGB1 was also rapidly released from
neurons to medium. Incubation with medium from neurons up-regulated IL-1β in mixed glial cells. This effect
could be inhibited by HMGB1 specific inhibitor glycyrrhizic acid (GA) treatment.
Conclusion: HMGB1 was released from neurons early after SAH onset and might trigger inflammation as an
upstream inflammatory mediator. Extracellular HMGB1 contributed to the brain injury after SAH. These results
might have important implications during the administration of specific HMGB1 antagonists early in order to
prevent or reduce inflammatory response following SAH.
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Subarachnoid hemorrhage (SAH), especially aneurysm
subarachnoid hemorrhage, is a life-threatening disease
of the central nervous system (CNS). The incidence of
SAH is about 22.5 cases per 100,000 in the population
according to a World Health Organization study [1]. Al-
though it has relatively low incidence, the early age of
onset and poor outcome results in a many life-years
lost. Toll like receptors (TLRs), myeloid differentiation
primary response protein 88 (MyD88), NF-κB, IL-1β
and TNF-α have been proved to participate in the dam-
aging inflammation process after SAH [2-5]. Moreover,
clinical studies have shown that increased levels of pro-
inflammatory factors in cerebrospinal fluid (CSF) and
serum of SAH patients are associated with poor out-
come [6,7]. Elevated inflammatory factors contribute to
the breakdown of the blood brain barrier (BBB), brain
edema, neuroglia cells apoptosis and death [8]. Adminis-
tration of the antagonists of the pro-inflammatory factors
confers a neuroprotective effect in library experimental
studies [2,5]. However, how the inflammatory response
is initiated and upstream of the inflammation response
is still poorly investigated.
High-mobility group box 1(HMGB1), as a nonhis-
tone protein binding with DNA, is widely expressed in
the nucleus of nearly all eukaryotic cells, including
brain cells, and stabilizes nucleosome formation, facili-
tates gene transcription [9]. Growing evidence shows
that HMGB1 is passively released from necrotic cells
or actively secreted from immune cells or non-immune
parenchymal cells under various pathological condi-
tions [9]. Extracellular HMGB1 serves as alarmin
or damage-associate molecular pattern (DAMP) that
mediates cross-talk between damaged cells and rela-
tive healthy cells and triggers inflammatory response
after interaction with TLR2, TLR4 and receptors
for advanced glycation end-products (RAGE) [10,11].
Extracellular HMGB1 has been regarded as a late
inflammatory mediator in sepsis and as an early medi-
ator in ischemia-inducible models [10,12]. Individual
research into HMGB1 in the late stage of SAH has
shown that HMGB1 is highly expressed in a day-5
group in brain stem tissue in the rabbit SAH model
[13]. However, previous study suggested that brain
parenchymal cells were damaged in the early period
after SAH onset [14]. Further, HMGB1 passive trans-
location usually occurred in the damaged cells [9].
Thus, we supposed that the HMGB1 might translo-
cate early from nucleus to cytoplasm after SAH. Thus,
this study aims to identify whether HMGB1 transloca-
tion occurred early after SAH and also to detect the
expression level of HMGB1 in the early stage and
clarify the potential role of HMGB1 in brain injury
following SAH.Method and material
Animal preparation
Male Sprague-Dawley rats (280 to 320 g) were purchased
from the Animal Center of Jinling Hospital. The rats were
raised in a 12-h dark-light cycle with free access to food
and water. All procedures were approved by the Animal
Care and Use Committee of Nanjing University and con-
formed to Guide for the Care and Use of Laboratory Ani-
mals by National Institutes of Health. Forty-five animals
were divided randomly into a sham group and SAH
groups at 2 h and 12 h, and on day 1 and day 2 respect-
ively (nine rats per group). Six rats from each group were
randomly selected for the analysis of western blot and
real-time PCR. In the following step, another 27 rats were
prepared for immunohistochemical and immunofluores-
cence study in the sham group, the 2-h, and the day-1
group (nine rats per group). Six rats each of the selected
groups were randomly chosen and sacrificed for immuno-
histochemical and immunofluorescence study. As for sub-
arachnoid injection of recombinant HMGB1 (rHMGB1),
45 rats were randomly divided into a control group and
rHMGB1 injection groups including 2-h, 12-h, day-1 and
day-2 groups (9 rats per group). Meanwhile, another 18
rats were prepared for immunofluorescent analysis (9 rats
in the control and day-1 group, respectively).
SAH model
The prechiasmatic injection model was used [15]. Briefly,
after intraperitoneal anesthesia with pentobarbital sodium
(50 mg/kg) (Sigma, St Louis, MO, USA),then they were
positioned prone in a stereotactic frame. After careful dis-
infection, a midline scalp incision was made and a 1-mm
hole was drilled 7.5 mm anterior to the bregma in the
midline, at an angle of 30°E caudally. Then they were posi-
tioned supine. After careful disinfection again we used an
insulin injection needle (BD Science, Franklin Lakes, New
Jersey, USA) to obtain 300 μl blood of themselves from
femoral artery. The needle was advanced 11 mm into the
prechiasmatic cistern through this burr hole, and the
300 μl blood was injected into the prechiasmatic cistern
over 20s. Sham rats experienced the same procedure except
for injection of 300 μl blood. Cerebral blood flow was moni-
tored for 45 minutes and 60 minutes after SAH. After com-
pleting these procedures, 1 ml of 0.9% NaCl was injected
subcutaneously to prevent dehydration and the rats were
arranged in the recovery cage. It took about 30 minutes to
one hour to reach recovery. After the rats started to move
around and eat some semi-fluid food, they were returned
to their clean and new cages and housed at 23 ± 1°C.
Subarachnoid prechiasmatic injection of recombinant
HMGB1
Prechiasmatic injection animal models were prepared as
mentioned above and injected with 150 μl recombinant
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from Human Embryonic Kidney 293 cells (HEK-293)
was prepared from Novoprotein(catalog number: C357,
purity >95%, PH 7.4, Summit, NJ, USA). The content of
endotoxion was tested by the Novoprotein Company
and found to be less than 0.1 ng/μg. This result was also
confirmed by our endotoxin Limulus amebocyte lysate
test (catalog number: KC48, Chinese Horseshoe Crab
Reagent Maunfactory, Xiamen, China). Western blot
analysis was designed to exclude Histone 3 protein con-
tamination. 50 μg rHMGB1 was diluted to 1,500 μl
(33 μg/ml) with saline and sterilized by filtration through
a 0.22-μm sterile filter in case of bacterial contamin-
ation. The dose of rHMGB1 was determined according
to Qiu’s research (3.3 μg rHMGB1/kg) [16] and adjusted
the total volume of injection to be 150 μl. Rats in the
control group were injected with 150 ul saline. Tissue
was prepared for western blot and immunofluorescent
analysis.
Perfusion-fixation and tissue preparation
Animals were sacrificed according to the time points of
different groups. In our pilot study, we found that there
was no statistical difference in any detected variables
among sham groups at any time point (data not shown).
Therefore, animals in the sham group were sacrificed at
24 h after the sham operation. Animals were anesthetized
as above, and perfused through the left cardiac ventricle
with 0.9% a NaCl solution until effluent from the right
atrium was clear. Animals that had obvious clots in the
prechiasmatic cistern were selected to further analyze.
The temporal lobe tissue (black box in Figure 1B), which
was near the hematoma, was harvested on ice after blood
clots on the tissue were carefully cleared. The tissue wasFigure 1 Schematic observation of the brain after surgery. Top: rat bra
onset. Rat brains in the sham group were harvested one day after the surg
subarachnoid space gradually disappeared with time (B to E). Bottom: rat b
recombinant High-mobility group box 1 (rHMGB1) saline (G to J). Rats in th
after the surgical procedure (F).stored at -80°C till further use for western blot, real-time
PCR. For immunohistochemistry and immunofluores-
cence study, the rats were perfused with 0.9% NaCl so-
lution followed by 4% buffered paraformaldehyde. A
coronal block cut from 4 mm to 6 mm and 6 mm to
8 mm anterior to the groove between forebrain and
cerebellum was prepared and immersed in 4% buffered
paraformaldehyde overnight and then embedded in
paraffin for immunohistochemistry study and frozen in
optimal cutting temperature (OCT) medium for im-
munofluorescence study, respectively.
Primary cortical neuron culture, hemoglobin (Hb)-incubated
neuron injury model and experimental design
The primary cortical neuron culture was prepared and
cultured as per the established technique in our labora-
tory. Specifically, timed-pregnant female rats (16 to 18 days
gestation) were sacrificed with deep anesthesia, and put in
75% alcohol disinfectant for sterilizing. Then 10 to 14 em-
bryos were removed by Caesarean section using sterile
techniques. The cortex was separated with the aid of a dis-
section microscope and rinsed with pre-cooling PBS and
treated by 0.1% trypsin for 5 minutes at 37°C, and then
the supernatant containing trysin was discarded and
washed by pre-cooling PBS. Subsequently, cells were tritu-
rated with fire-polished glass pipettes. Then the neuron
suspension was filtered through a 22 μm-filter into a
15 ml conical tube and sedimented at 1500 r/minute for
5 minutes at 4°C. After centrifugation, cells were resus-
pended in neurobasal media with B27 (GIBCO, Rockville,
MD, USA) plus antibiotics and were dissociated by re-
peated pipetting through a 1-ml blue pipette tip. Then the
cells were planted at approximately 100 × 104 cells per
well in 6-well ploy-D-lysine-coated plates. Cultures wereins harvested at different times after subarachnoid hemorrhage (SAH)
ical procedure (A). We can conclude that blood clot in the
rains harvested at different times after subarachnoid injection of
e control group were injected with 0.9% saline, and sacrificed one day
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CO2 and 95% air. Subsequently, half of the medium was
replaced every 2 days during the first 8 days in vitro. The
cultures were used on day 8when the cultures were essen-
tially free of astrocytes. Hemoglobin (Hb) provided react-
ive oxygen species (ROS) and heme, which caused neuron
cell injury. Thus, Hb incubation in cultured neurons is
often used as a neuron injury model in the researches of
hemorrhage disease, including SAH. In this study, this
model was also employed as the experimental SAH in the
in vitro model. Hb (sigma, St. Louis, MO, USA) were pre-
pared and resolved into 10 μM with culture medium and
sterilized by filtration through a 0.22-μm sterile filter.
Then the neurons were treated with Hb at a concentration
of 10 μM, which was determined from prior studies [17].
After 4, 8, 16 and 24 h, the media of neurons were con-
centrated for protein analysis and cultured neurons were
arranged for immunofluorescence staining.
Primary mixed glial cells culture and cell medium
stimulation experimental design
Primary mixed glial cells cultures were prepared as pre-
vious study [10]. Briefly, cerebral hemispheres of 1- to
3-day-old postnatal rat brains (Sprague-Dawley rats)
were separated with the aid of a dissection microscope
and rinsed with pre-cooling PBS and treated by 0.125%
trypsin for 5 minutes at 37°C, and then DMEM contain-
ing 10% FBS(Hyclone, Logan, Utah, USA) were added to
stop the digestion process. Subsequently, cells were trit-
urated by repeated pipetting through a 1-ml blue pipette
tip. Then the suspension was filtered through a 22 μm-filter
into a 15-ml conical tube and sedimentedat 1,500 r/minute
for 5 minutes at 4°C. After centrifugation, cells were resus-
pended and planted at approximately 100 × 104 cells per
well in 6-well plates in DMEM (Hyclone, Logan, Utah,
USA) containing 10% FBS(Hyclone, Logan, Utah, USA).
Culture media were renewed after 24 h and then twice per
week. After 1 week, cells were subjected to different
treatments.
Cell medium preparation: neuron cells were cultured
as was described above. After incubation with neuroba-
sal medium containing 20 μmol Hb for 2 h, the medium
was removed and replaced with fresh DMEM. After neu-
rons with DMEM were cultured for 22 h, the DMEM
medium was collected as the neuron medium. The con-
trol medium was prepared from neurons treated with
neurobasal containing 0 μmol Hb and incubated with
DMEM medium for 22 h.
Groups and experiment design: cultured mixed glial
cells were arranged into three groups. The control
group: mixed glial cells treated with control medium;
the medium group: mixed glial cells treated with neuron
medium; the glycyrrhizic acid (GA) group: after mixed
glial cells were treated with neuron medium, GA (Sigma,catalog number:50531, purity >95%, St. Louis, MO, USA)
diluted in PBS and adjusted PH to 7.4, then added to
medium, the final concentration of GA in medium was
2 mM), a special inhibitor of HMGB1 was added in the
medium to silence the activity of HMGB1 [18,19]. Mixed
glial cells in all the groups were cultured for another 24 h.
Then, glial cells were collected for real-time PCR analysis.
Preparation of tissue protein for western blot analysis
Total protein extraction
Proper size of tissues (50 ~ 100 mg) were completely ho-
mogenized using buffer and centrifuged at 14,000 × g for
15 minutes at 4°C. The supernatant was collected as the
total protein extraction of tissue.
Cytosolic/nuclear fraction extraction
Rat brain-tissue cytosolic/nuclear fraction extraction
was performed following the methods used in our la-
boratory [20]. The brain tissue (about 100 mg) was ho-
mogenized in 1 ml ice-cold buffer A composed of
10 mMHEPES (pH 7.9), 2 mMMgCl2, 10 mM KCl,0.1 mM
EDTA, 1 mMdithiothreitol (DTT) and 0.5 mM phenyl-
methylsulfonyl fluoride (PMSF) (all from Sigma Chemical
Co).The homogenate was incubated on ice for 20 minutes,
and then 30 μl of 10% NonidetP-40 solution was added
(Sigma, St. Louis, MO, USA); the mixture was vortexed
for 30 s and spun by centrifugation for 10 minutes at
5,000 g, 4°C. The cytosolic fraction extracts were collected
and stored at -80°C for western blot analysis. The crude
nuclear pellets were suspended in 200 μl ice-cold buffer B
containing 20 mM HEPES (pH 7.9), 25% (v/v) glycerol,
1.5 mM MgCl2, 20 mMKCl, 0.1 mM EDTA, 0.5 mM
PMSF, and 1 mM DTT, and incubated on ice for 30 mi-
nutes with intermittent mixing and centrifuged at
12,000 g at 4°C for 15 minutes. The supernatant contain-
ing nuclear proteins was collected and stored at -80°C for
western blot analysis. Protein concentration was deter-
mined using a bicinchoninic acid assay kit with bovine
serum albumin as the standard (Pierce Biochemicals,
Rockford, IL, USA).
Western blot analysis
For western blot analysis, an equal volume of 5 × SDS
sample buffer was added to the protein extraction, and
the samples were then boiled for 5 minutes. Samples
(70 μg per lane) were subjected to electrophoresis 10%
SDS-polyacrylamide gels for 30 minutes at 80 V followed
by 100 minutes at 110 V and then transferred onto polyvi-
nylidenefluoride (PVDF) for 2 h at 200 mA. The mem-
brane was blocked with 5% defatted milk for 2 h at room
temperature, then incubated with primary antibodies at 4°C
with gentle shaking overnight. We used anti-HMGB1
monclonal antibody (Catalog no. 2600-1, Epitomics, Inc.,
Burlingame, CA, USA, diluted 1 : 5000), anti-NF-κB(P65
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(Cell signaling technology, Beverly, MA, USA 1:1000 dilu-
tion)and β-actin (Catalog no.AP0060, Bioworld, USA, 1:
3000 dilution) After that the membrane was washed for
10 minutes each for four times in TBS + Tween 20
(TBST), followed by incubated in the appropriate HRP-
conjugated secondary antibody (Catalog no. BS13278, Bio-
world, USA, diluted 1:5000 in TBST) for 2 h at room
temperature. The blotted protein bands were visualized by
enhanced chemiluminescence (ECL) western blot detec-
tion reagents (Catalog number NCI5079, Thermo Scien-
tific, Rockford, IL, USA) and were exposed to x-ray film.
Relative changes in protein expression were estimated
from the mean pixel density using UN-SCAN-IT, normal-
ized to β-actin, and calculated as target protein expression/
β-actin expression ratios.RNA isolation and quantitative real-time PCR
Rat brain tissues were isolated using TRIzol Reagent
(TAKARA Biotechnology, Japan) as per the manufac-
turer’s instructions. The concentration of the RNA was
determined by spectrophotometric analysis (OD260/280).
The quantity of RNA was measured using OD260. The
isolated RNA was stored at-80°C until analyzed. RNA was
reverse-transcribed to cDNA using Reverse Transcriptase
Reagent (TAKARA Biotechnology, Japan) and oligodT
primers. Quantitative real-time PCR analysis was performed
using the Agilent Technologies Stratagene Mx3000P real-
time PCR system (Genetimes Technology, Inc), applying
real-time SYBR Green PCR technology. The reaction mix-
tures contained 1 μl cDNA, 12.5 μl SYBR Green (TAKARA
Biotechnology, Japan), 1 μl of each forward and reverse
primer (10 μM) and nuclease-free water to a final volume
of 25 μl. The primers were synthesized by Life Technolo-
gies (Invitrogen, Shanghai, China) and the sequences used
were from a database at NCBI for rat HMGB1, TNF-Θ,
IL-1β and β-actin. HMGB1 forward and reverse primers
were 5’-ATGGGCAAAGGAGATCCTA-3’ and 5’-ATTC
ATCATCATCATCTTCT-3’; TNF-Θ forward and reverse
primers were 5’-TGCCTATGTCTCAGCCTCTTC-3’ and
5’-GAGGCCATTTGGGAACTTCT-3’; IL-1β forward and
reverse primers were 5’-TGAGCACCTTCTTTTCCTTC
A-3’ and 5’-TTGTCTAATGGGAACGTCACAC-3’; β-
actin forward and reverse primers were 5’-AGGG
AAATCGTGCGTGAC-3’ and 5’-CGCTCATTGCCG
ATAGTG-3’. After 95°C for 30 s, 40 PCR cycles were
performed; each consisting of a denaturation step (95°C,
5 s) and an annealing step (60°C, 30 s). Total RNA
concentrations from each sample were normalized by
quantity of β-actin mRNA, and the expression levels of
target genes were evaluated by ratio of the number of
target mRNA to β-actin mRNA. All samples were ana-
lyzed in triplicate.Administration of propidium iodide and detection of
propidium iodide-positive cells
Propidium iodide (PI), 10 mg/ml (Sigma, St Louis, MO,
USA) was diluted in 0.9% NaCl and 1 mg/kg was admin-
istered 1 h prior to sacrifice by intraperitoneal injection
in a total volume of not more than 100 μl. Brain tissue
was fixed with 4% paraformaldehyde overnight and
dipped in 20% saccharose PBS for 2 days and then in
30% saccharose PBS for another 2 days to remove water
in the tissue. For detection of the relationship between
PI-labeled and HMGB1-positive cells, sections 6 μm in
thickness were sliced and blocked with 5% normal FBS
in PBS containing 0.1% Triton X-100 for 2 h at room
temperature prior to incubation with anti-HMGB1 anti-
body(diluted 1:500, Epitomics, Burlingame, CA, USA)
overnight at 4°C. After sections were washed three times
with PBS for 45 minutes, they were immunolabeled with
secondary antibody (Alexa Fluor 488 diluted 1:200) for
1 h at room temperature. The slides were washed with
PBS again three times for another 30 minutes prior to
being counterstained by 4',6-diamidino-2-phenylindole
(DAPI) for 2 minutes. After three more washes, the
slides were covered by microscopic glass with Anti-fade
Mounting Medium for further study. The whole process
was conducted with careful prevention of light.
Immunohistochemical staining
Coronal blocks cut from 4 mm to 6 mm anterior to the
groove between the forebrain and cerebellum in each rat
brain were prepared for immunohistochemistry. The tis-
sue was fixed with 4% paraformaldehyde and embedded
in paraffin. The tissue sections (4 μm) were used for im-
munohistochemical staining (Figure 2D). The sections
were deparaffinaged as usual and incubated with 3% H2O2
in PBS for 10 minutes. Sections were incubated with
an anti-HMGB1 monclonal antibody diluted 1:500(Ep-
itomics, Burlingame, CA, USA). Pilot experiments with
blocking peptides were performed to validate the spe-
cificity of primary antibodies before the experiments.
Negative controls were prepared by omitting the primary
antibodies. Each of the sections was incubated with horse-
radish peroxidase (HRP)-conjugated goat anti-rabbit IgG
diluted 1:500(Santa Cruz Bio-technology, Santa Cruz, CA,
USA) for 60 minutes at room temperature. Diaminobenzi-
dine (DAB) was used as the chromogen and counterstain-
ing was done with hematoxylin. Three coronary sections
in each coronal block sample with a minimum of 100 μm
from the adjoining section were used for cell counting
in each sample. The number of cytoplasmic HMGB1-
positive cells was presented as the percentage of total cells
in each visual field. Three randomly non-overlapping
high-power areas (×400) per section were selected and
observed in the cortex as shown in the black box in
Figure 2D. Then mean percentage of cytoplasmic HMGB1-
Figure 2 Representative immunohistochemistry analysis of High-mobility group box 1 (HMGB1) in the brain cortex. (A) HMGB1
expression in the sham group: HMGB1 could be observed in the nucleus in the sham group, cells were seldomly stained positive for cytosolic
HMGB1. (B, C) HMGB1 staining in the 2-h and day-1 groups post subarachnoid hemorrhage (SAH), respectively. The quantity of cells positive for
cytosolic HMGB1 obviously increased in the SAH groups at 2 h and day 1 after SAH. (D) Black boxes show the view of observation. (E, F and G)
Enlarged images of A, B and C, respectively. Positive cells were defined as presenting buffy grains in cytoplasm as shown by arrows. Scalar bars
present 20 μm. (H) Quantification of density of cells positive for cytosolic HMGB1. Values were obtained from averaging three sections per animal.
SAH induced translocation of HMGB1 in the cortex near the subarachnoid space as early as 2 h post SAH. Bars represent the mean ± standard
error (n = 6); #P < 0.01 compared with the sham group.
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each section. The final average percentage of the three sec-
tions was regarded as the data for the sample. Six samples
in each group, respectively, were used for statistical analysis.
The percentage of HMGB1-positive cells was identified,
calculated, and analyzed under the light microscopy by an
investigator blinded to the grouping.
Immunofluorescence staining
Immunofluorescence staining was performed according
to our previous study in our laboratory [3]. Brain tissue
was fixed with 4% paraformaldehyde overnight and
dipped in 20% saccharose PBS for 2 days and then in
30% saccharose PBS for another 2 days to remove
water in the tissue. Sections 6 μm in thickness were
sliced and blocked with 5% normal FBS in PBS con-
taining 0.1% Triton X-100 for 2 h at room temperature
prior to incubation with anti-neuron-specific nuclear
protein (NeuN) antibody (Millipore, MA, USA, 1:200)
and anti-HMGB1 antibody diluted 1:500(Catalog num-
ber 2600-1,Epitomics, Burlingame, CA, USA) or anti-
ionized calcium binding adaptor molecule 1 (Iba1)
antibody (Abcam, MA, USA,1:200) and anti-HMGB1
antibody diluted 1:500(Epitomics) or anti-glial fibrillary
acidic protein (GFAP) antibody (1:200, BD Science, Franklin
Lakes, New Jersey, USA) and anti-HMGB1 antibody diluted
1:500(Epitomics) or anti-cleaved caspase-3 diluted 1:500
(Cell Signaling Technology, Beverly, MA, USA) and NeuN
antibody (Millipore, MA, USA, 1:200) overnight at 4°C.
After sections were washed three times with PBS for
45 minutes, they were immunolabeled with proper sec-
ondary antibodies (Alexa Fluor 488 and Alexa Fluor 594,
1:200) for 1 h at room temperature. The slides werewashed with PBS again three times for 45 minutes prior
to being counterstained by DAPI for 2 minutes. After
three further washes, the slides were covered by micro-
scopic glass with Anti-fade Mounting Medium for further
study. Pilot experiments with blocking peptides were per-
formed to validate the specificity of primary antibodies be-
fore the experiments. Negative controls were prepared by
omitting the primary antibodies. Fluorescence microscopy
imaging was performed using ZEISS HB050 inverted
microscope system and handled by Image-Pro Plus 6.0
software (Media Cybernetics, USA). and Adobe Photo-
shop CS5 (Adobe Systems, San Jose, USA).
HMGB1 measurements of cell-conditioned medium
Cell-conditioned medium was ultrafiltered and analyzed
by western blot. Briefly, cell-conditioned medium (4 ml)
was ultrafiltered using a Centricon (10 kDa, 4 ml, Millipore,
MA, USA) according to the Instrument Manual at 4,000 ×
g with a typical final concentrate volume of about 100 μl.
Sometimes more ultrafiltration tubes were required because
Hb in the medium sometimes blocked the hole in the
Centricon. About one third of the final volume was sub-
jected for western blot analysis as described above. The
primary antibodies wasanti-HMGB1 diluted 1:500(Epi-
tomics, Burlingame, CA, USA). Detection was performed
using detection reagents (Catalog number NCI5079,
Thermo Scientific, Rockford, IL, USA) and were ex-
posed to an x-ray film kit (Thermo Scientific, Rockford,
IL, USA).
Statistical analysis
All data were presented as mean ± standard error of the
mean (SEM). SPSS 17.0 was used for statistical analysis
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way analysis of variance (ANOVA). Differences between
experimental groups were determined by the Student
t-test. A value of P < 0.05 was considered statistically
significant.Result
General observation
In all the experimental SAH animals (n = 72), 6 of 54
(11.1%) animals injected with blood died while no ani-
mals died in the sham group. All mortality occurred
within 24 h of surgery. Two rats with SAH were ex-
cluded from the study because of too little blood in the
prechiasmatic cistern but many blood clots in the frontal
lobe instead. Compared to the sham group (Figure 1A),
the blood clots could easily be found on surface of the
temporal lobe and around the basilar arteries (Figure 1B
to E). It was also demonstrated that the blood clot in the
subarachnoid space disappeared gradually with time
(Figure 1B to E). No blood clots were found in the saline
control group or in rHMGB1 injected groups (Figure 1F
to J), and no rats in the control group died, while 3 of
45 rats died within 24 h after injection of rHMGB1.HMGB1 expression in the sham-group brain
In the sham-group rat-brain coronal sections, HMGB1
was observed to be widely expressed in the nuclei of brain
cells (Figure 2A), in either NeuN, GFAP, or Iba-1-positive
cells (Figures 3D, 4C and 5C).Figure 3 Cytosolic expression of high-mobility group box 1 (HMGB1)
from animals with subarachnoid hemorrhage (SAH). (A, B, C) HMGB1 i
SAH (B), and a day-1 (C) animal respectively. (D, E, F) Merged images of H
nuclear staining (blue). (G, H, I) Merged images of HMGB1 immunostaining
right side of each panel highlight the increased number of NeuN-positive c
Arrows indicate the cytosolic HMGB1. The mark (>) indicates co-localization
translocation occurred as early as 2 h and advanced in the process after SASubarachnoid hemorrhage induction induces HMGB1
translocation and release in brain cells
HMGB1 was reported as a late responding signal mol-
ecule in sepsis [12]. Individual study indicated that
HMGB1 level was increased in the late stage of SAH
[13]. Little is known about the role of HMGB1 in the
early stage of SAH. Thus, we examined a series of early
time points in the rat SAH model to obtain a full view
of HMGB1 protein level and location changes after
SAH. Firstly, through western blot analysis of total tissue
extracts, the level of HMGB1 protein increased signifi-
cantly as early as 2 h after experimental SAH onset and
peaked on day 1 post SAH when compared to the sham
group(2 h, P < 0.05; 12 h, P < 0.01; day 1, P < 0.01; day 2,
P < 0.05) (Figure 6A). To identify whether the increased
level of HMGB1 protein was transferred from nucleus to
cytoplasm, nuclear protein fraction and cytosolic protein
fraction were extracted separately (see Method and ma-
terial). HMGB1 protein level in the cytosolic protein
fraction was detected to significantly increase as early as
2 h after SAH induction (2 h, P < 0.01; 12 h, P < 0.01;
day 1, P < 0.01) (Figure 6B). The above results showed
that SAH could cause significant increased production
and translocation of HMGB1 protein in the brain cortex
as early as 2 h post injury.
Through quantitative real-time PCR analysis, the mRNA
level of HMGB1 in SAH groups was identified to increase
compared to the sham group. In detail, low level mRNA
of HMGB1 could be detected in the sham group while the
HMGB1 mRNA expression was significantly higher in ain Neuron-specific nuclear protein(NeuN)-positive cells of cortex
mmunostaining images obtained from the cortex of a sham (A), a 2-h
MGB1 immunostaining (red) and 4',6-diamidino-2-phenylindole(DAPI)
(red) and NeuN immunostaining (green). Enlarged images on the
ells with cytosolic staining of HMGB1 in cortex from SAH animals.
of cytosolic HMGB1 and NeuN, The results indicate that HMGB1
H. Scale bars represent 20 μm.
Figure 4 Cytosolic expression of High-mobility group box 1 (HMGB1) in Glial fibrillary acidic protein (GFAP)-positive cells of cortex
from animals with subarachnoid hemorrhage (SAH). (A, B) HMGB1 immunostaining images obtained from cortex of a sham (A), and a day-1
(B) animal respectively. (C, D) Merged images of HMGB1 immunostaining (red) and 4',6-diamidino-2-phenylindole (DAPI) nuclear staining (blue).
(E, F) Merged images of HMGB1 immunostaining (red) and GFAP immunostaining (green). Enlarged images (a, b, c, d, e, f) on the right side of
each panel also highlight the increased number of cytosolic HMGB1-positive cells in cortex from SAH animals while few cytosolic HMGB1-positive
cells were also positive for GFAP. Arrows indicated the cytosolic HMGB1. The results indicated that astrocytes were not the main source of
released HMGB1, at least at this early time point. Scale bars represent 20 μm.
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SAH groups. A statistical difference was found not
only between the sham and 2-h group (P < 0.05) but
also between the sham group and the 12-h, day-1
groups (P < 0.01, respectively) (Figure 6C). The above
results showed that SAH could cause significant active
production of HMGB1 in the brain cortex as early as
2 h post injury.
HMGB1 translocation and release from brain cells was
also confirmed by immohistochemistry study. The extra-
nucleus or cytoplasm-positive HMGB1 staining cells were
regarded as HMGB1-positive cells. As Figure 2B shows,
HMGB1 translocation in the cortex occurred as early as
2 h after SAH. This result is in agreement with our west-
ern blot result (Figure 6B). The amount of cytoplasm
HMGB1-positive cells could be observed to increase sig-
nificantly in representative cortex from the 2-h (mean =
17.03%) to day-1 group (mean = 38.57%) (Figure 2F,G)
compared to the sham group (mean = 2.63%). Semi-
quantitative analysis showed that there was an obvious dif-
ference between the sham group and the 2-h, day-1 group
(P < 0.01) (Figure 2H).Early HMGB1 translocation induced by SAH occurred
mostly in neurons in brain tissue
Double immunofluorescent staining was performed for
HMGB1 and NeuN, Iba1 or GFAP to identify the cell
types in which HMGB1 translocation occurred after
SAH. We examined several time points in the SAH rat
model to confirm the translocation of HMGB1 and
how early it occurred after SAH. As Figure 3 shows,
most cytosolic HMGB1-positive cells were also posi-
tive for NeuN-staining. In comparison with the sham
group, SAH also induced HMGB1 translocation in
cells positive for Iba-1 (Figure 5). Few cells were found
to stain positive for cytoplasmic HMGB1 and GFAP
(Figure 4). These results suggest that HMGB1 trans-
location mainly occurred in neurons in the injured
cortex following SAH. Meanwhile a small number of
Iba-1-positive cells started to secrete HMGB1 in the
early phase following SAH. These findings may in part
reflect the selective vulnerability of neurons to the in-
jury and suggest that neurons might be one of the
main sources of the released HMGB1, at least in this
early phase.
Figure 5 Cytosolic expression of High-mobility group box 1 (HMGB1) in ionized calcium binding adaptor molecule 1 (Iba1)-positive
cells of cortex from animals with subarachnoid hemorrhage (SAH). (A, B) HMGB1 immunostaining images obtained from cortex of a sham
(A) and a day-1 SAH (B) animal. (C, D) Merged images of HMGB1 immunostaining (red) and 4',6-diamidino-2-phenylindole (DAPI) nuclear staining
(blue). (E, F) Merged images of HMGB1 immunostaining (red) and Iba1 immunostaining (green). Enlarged images (a, b, c, d, e, f) on the right side
of each panel highlight the increased number of cytosolic HMGB1-positive cells (arrows) in cortex from SAH animals and some cytosolic HMGB1-positive
cells were also positive for Iba1(shown as >). Scale bars represent 20 μm. Arrows indicat the cytosolic HMGB1. The mark (>) indicates co-localization of
cytosolic HMGB1 and Iba-1. The results indicate that microglia were also a source of extracellular HMGB1. Scale bars represent 20 μm.
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in the increased level of HMGB1
To give support to the hypothesis that both passive and
positive release of HMGB1 were engaged in HMGB1
translocation. PI staining was employed to distinguish
the dead cells and survival cells [21]. As Figure 7 shows,
seldom cells were stained for PI in the sham group while
PI-positive cells could be easily found in the 2-h and
day-1 groups (Figure 7B,G,L,Q). Cells positive for PI
and cytoplasmic HMGB1 were observed both in the 2-h
and day-1 groups, which indicates that these cells were in
an injured condition and HMGB1 might be released
passively (Figure 7J,O) [9]. However, HMGB1 cytoplasm-
positive cells that were not positive for PI were also de-
tected in another representative view of the day-1 group
(Figure 7T), which means these cytoplasmic HMGB1 were
actively secreted. These results were also in agreement
with our real-time PCR result.
Extracellular HMGB1 induces inflammatory cytokines and
cleaved caspase3 activity in vivo
TLR4 is the important receptor of HMGB1. Western
blot of total protein extraction demonstrated that
rHMGB1 induced increased level of TLR4 (P < 0.05between the control group and 12-h group; P < 0.01 be-
tween the control group and day-1, day-2 groups respect-
ively) (Figure 8B). This result indicates that extracellular
HMGB1 could initiate TLR4 signal pathway. NF-κB activ-
ity is usually measured by electrophoretic mobility shift
assay (EMSA) [22] and nuclear translocation of its main
proinflammatory subunit P65 [23,24]. Thus, the protein
level of P65 in the nucleus extract is usually used to evalu-
ate the activity of NF-κB in our laboratory [25,26]. The
nuclear extract was prepared for western blot analysis of
NF-κB(P65). As Figure 8A shows, the P65 subunit in the
nucleus was significantly increased in the 12-h, day-1,
day-2 groups after injection of rHMGB1 (12 h, P < 0.05;
day 1, P < 0.05; day 2, P < 0.01). The downstream inflam-
matory factor IL-1β, was also detected to be up-regulated
by real-time PCR (12 h, P < 0.05; day 1, P < 0.01; day 2,
P < 0.05) (Figure 8C). Cleaved caspase 3 staining, a pos-
sible marker of apoptosis, was used to evaluate the brain
injury after rHMGB1 injection. Compared with the con-
trol group, the number of cells positive for cleaved cas-
pase 3 and NeuN was increased, which suggested that
rHMGB1 might be a harmful molecule for brain cells,
especially for neurons (Figure 9) and extracellular HMGB1
might contribute to the brain injury after SAH.
Figure 6 Expression of High-mobility group box 1 (HMGB1) protein and mRNA level in brain cortex after subarachnoid hemorrhage
(SAH). (A) Western blot analysis of HMGB1 expression in the total protein extraction of the cortex after SAH showed that the HMGB1 protein
level was significantly increased as early as 2 h and peaked approximately on day 1. (B) Western blot analysis of HMGB1 in the cytosolic protein
fraction of the cortex. The quantity of HMGB1 protein in cytosolic protein fraction was also detected to increase in the 2-h, 12-h, day-1 and day-2
groups, which indicated that the HMGB1 translocation occurred as early as 2 h after SAH onset. (C) Real-time PCR analysis of HMGB1 mRNA level
demonstrated the HMGB1 mRNA level was also up-regulated as early as 2 h after SAH. Bars represent the mean ± standard error (n = 6, each
group). #P < 0.01 compared with the sham group; *P < 0.05 compared with sham group.
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To confirm the neuronal susceptibility of early HMGB1
translocation, primary cortical neuron culture was sub-
jected to Hb treatment and HMGB1 translocation was
detected by immunofluorescence staining and western
blot. Immunofluoresecnce staining showed more than
98% cells were positive for both NeuN (green) and DAPI
(blue) which suggested the high percentage of neurons
in the primary cultured cells (Figure 10A). Through
western analysis, HMGB1 was undetectable in medium
from untreated cells. However, HMGB1 was found to
accumulate in culture medium of Hb-incubated neu-
rons (Figure 10B). A phase-contrast micrograph of neu-
rons demonstrated cellular morphology of untreated
(Figure 10C) and 24-h Hb (Figure 10D). Furthermore,
HMGB1 was detected as nucleus-positive in The con-
trol group (Figure 10E) and cytoplasm-positive in Hb-
treated groups (Figure 10F). This result indicates that
HMGB1 in neurons was in a process from nucleus to
extracellular after Hb incubation.
Conditioned medium from Hb-treated neurons induced
IL-1β in cultured mixed glial cells, which could be
inhibited by HMGB1-specific inhibitor
To determine whether HMGB1 released from injured cul-
tured neurons was biologically active as a pro-inflammatory
mediator, we treated primary mixed glial cell cultures withconditioned medium from Hb-treated neurons. To remove
residual Hb in supernatant, neurons were cultured in
fresh DMEM after being exposed to Hb (20 μmol) for
2 h. As shown in Figure 11, conditioned medium ro-
bustly induced IL-1β mRNA expression in glial cells.
However, IL-1β could be inhibited after treatment with
HMGB1-specific inhibitor GA (P < 0.01 between the con-
trol and medium group; P < 0.05 between the medium
group and medium +GA group). This result indicates that
HMGB1 in the medium played an important role in acti-
vation of glial cells.
Discussion
In this study, we demonstrated that (1) HMGB1 was
translocated from the nucleus to the cytoplasm and re-
leased from neurons as early as 2 h after SAH associated
with a significant upregulation of protein and mRNA
level; (2) both passive and active release of HMGB1 were
involved in the process of HMGB1 translocation; (3)
rHMGB1 or HMGB1 released from neurons could induce
inflammatory response, and (4) extracellular HMGB1 con-
tributed to the early brain injury after SAH.
Previous studies have demonstrated that HMGB1 could
be released from necrotic cells passively or secreted ac-
tively from immune cells or non-immune parenchymal
cells, such as hepatocytes,in ischemia [27,28]. In our study,
we demonstrated that HMGB1 was released from cortex
Figure 7 Representative photomicrographs show brain cortex double-staining of immunofluorescent (High-mobility group box 1
(HMGB1), green) and PI staining (red) in the sham (A - E), 2-h (F - J), day -1 (K - O), and another day-1 (P - T) group. The nucleus was
counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue) in the same view in each section. (D, I, N, S) Merged images of HMGB1(green)
and DAPI (blue); (E, J, O, T) merged images of propium iodide (PI) (red) and HMGB1 (green). Compared with the sham group (D), the
subarachnoid hemorrhage (SAH) groups (I, N, S) show translocation of HMGB1 from nuclear to cytoplasm (the mark (>) indicates the cytosolic
HMGB1). Few PI-positive cells could be observed in the sham group (B, E) while patches of cells positive for PI could be detected in the SAH
groups (G, L). Overlapping images (J, O) showed that most cells were positive for both cytosolic HMGB1 and PI staining (arrows indicate the
co-localization of cytosolic HMGB1 and PI). However, positive staining for cytosolic HMGB1 but not positive for PI staining could also easily found
in the day-1 group post SAH (T). Scale bar: 20 μm. These results support the theory that both passive and active release of HMGB1 are involved
in the translocation process.
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ing to our western blot and immunhistochemistry results.
Friedrich et al. showed that cortex cell death occurred as
early as 10 minutes after SAH [14]. As a consequence,
passive release of HMGB1 was possibly initiated by dam-
aged cellular integrity. This hypothesis was also supported
in our study, which showed co-location of PI staining and
cytosolic HMGB1 staining (Figure 7J). However, active se-
cretion of HMGB1 was also supported by up-regulated
mRNA and protein levels of HMGB1 (Figure 6A to C) in
our study. Further, positive staining for cytoplasmic
HMGB1 but negative for PI staining also support this the-
ory (Figure 7S,T). Our research was consistent with re-
search into liver ischemia, which has shown that the liver
parenchymal cell, liver cells could actively release HMGB1
under ischemic conditions [27,28]. Thus, it is possible that
both passive and active releases of HMGB1 are involved
in the process of HMGB1 translocation. However, co-
immunoprecipitation might be the best method to make
sure whether cytoplasmic HMGB1 was passive or activelyreleased [28]. Previous study indicated that both passive
and active release of HMGB1 have cytokine activity and
could trigger inflammatory response [29], thus co-
immunoprecipitation of HMGB1 was not performed in
this study.
Extracellular HMGB1 was regarded as a member of
the DAMP family [30]. HMGB1 functions as a pro-
inflammatory factor through its receptors, including
TLR2, TLR4 and RAGE [11]. Conceivably, up-regulated
expression of HMGB1 receptors after SAH might enhance
the sensitivity of brain cells to HMGB1. Both TLR4 and
RAGE were reported to ascend early after SAH in recent
studies [4,26,31]. Although interaction of HMGB1 with
these receptors signals through different pathways, they
ultimately promote the NF-κB/P65 translocation to nu-
cleus and activation of NF-κB, which activates the tran-
scription of downstream pro-inflammatory genes (IL-1β,
TNF-α) [11]. Addition of rHMGB1 in the subarachnoid
space up-regulated TLR4, P65 protein levels and down-
stream inflammatory response in this study, which
Figure 8 Addition of recombinant High-mobility group box 1 (rHMGB1) in the subarachnoid space triggered inflammatory response
in vivo. NF-κB was measured by the western blot of its P65 subunit in the nucleus. Toll-like receptor (TLR)4 protein level was also detected by
western blot analysis. IL-1β was measured by real-time PCR. (A) rHMGB1 up-regulated P65 subunit protein level in the nuclear protein in cortex
cells; P < 0.05 between the 12-h, day-1 group and control group, P < 0.01 between the day-2 group and control group. (B) rHMGB1 increased
TLR4 protein level. P < 0.05 between the 12-h and control group, P < 0.01 between the day-1, day-2 group and control group. (C) rHMGB1
upregulated IL-1β mRNA expression in cortex cells: P < 0.05 between the 12-h, day-2 group and control group, P < 0.01 between the day-1 group
and control group. (D) Western blot analysis of histone 3 content in rHMGB1(left lane) and the nuclear protein extraction(right lane). The result
could exclude histone 3 contamination in rHMGB1 products. Histone 3 was predominant composition of histone protein, thus, our result
indicated the rHMGB1 used in the study had good purity. Bars represent the mean ± standard error (n = 6): *P < 0.05 compared with the
control group; #P < 0.01 compared with the control group.
Figure 9 Representative photomicrographs showed brain neurons double immunofluorescent staining for cleaved caspase 3 (red) and
Neuron-specific nuclear protein (NeuN), a neuron cell marker (green) in vivo in the control (A to D) and recombinant High-mobility
group box 1 (rHMGB1) treatment group (E to H). The nucleus was counterstained with 4',6-diamidino-2-phenylindole (DAPI) (blue) in the
same view in each section. (D, H) Merged images of cleaved caspase 3 (red) and NeuN(green). Compared with the control group (A), more
cleaved caspase 3-positive cells were detected in the cortex after rHMGB1 treatment (E). Especially, overlapping images (H) showed that the
number of cells positive both for cleaved caspase 3 and NeuN increased compared with control group (D). The marks (>): profiles positive for
cleaved caspase 3 and DAPI but negative for NeuN showed activation of caspase 3 in non-neuronal cells. Arrows: profiles positive for cleaved
caspase 3 and NeuN showed activation of caspase 3 in neurons. Scale bar: 20 μm. These results indicate that rHMGB1 addition increased the
cleaved-caspase 3 positive cells, especially the neurons. RHMGB1 might promote the cell apoptosis.
Sun et al. Journal of Neuroinflammation 2014, 11:106 Page 12 of 16
http://www.jneuroinflammation.com/content/11/1/106
Figure 10 Representative photomicrographs showed brain neurons double immunofluorescent staining for High-mobility group box 1
(HMGB1) (red) and Neuron-specific nuclear protein (NeuN), a neuronal cell marker (green) in vitro in the control (C, E) and Hb incubation
group (D, F). (A) Immunofluorescence staining shows more than 98% cells were positive for both Neuron and 4',6-diamidino-2-phenylindole
(DAPI), which suggests the high percentage of Neuron cells in the primary cultured cells. (B) Result of western blot analysis of concentrated
conditioned culture media, which showed that HMGB1 could be detected in the media. (C, D) Images of cultured neurons in light microscopy to
watch its sharp; light micrograph of neurons shows cellular morphology in sham group (C) and Hb incubation group (D). (E, F) Merged images
of HMGB1(red) and DAPI (blue) in cultured neurons. Compared with the sham group (E), the Hb incubation groups (F) showed translocation of
HMGB1 in cytoplasm (as shown by white arrows). Scale bar: 20 μm.
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inflammatory response and the TLR4/NF-κB signal
pathway might be one of the activated inflammatory
pathway in HMGB1-induced inflammatory response.
Previous study has shown that the most important re-
ceptors of HMGB1, TLR4 and RAGE are up-regulated
4 h and 6 h after SAH, respectively. IL-1β reaches its
peak on day 1 after SAH [3,31]. In this study HMGB1
translocation was detected as early as 2 h post injury.
Furthermore, in vivo, we observed a two-fold induction
of IL-1β mRNA level after subarachnoid injection of
rHMGB1 (Figure 8C). Previous studies also demon-
strated that HMGB1 incubation in glia or neuron cells
in vitro induce 2- to 4-fold inflammatory factor mRNAinduction [10,22]. The data reported here showed the
translocation of HMGB1 preceded the increase of other
cytokines, which indicates that HMGB1 may act as an
early upstream initiator of inflammation after SAH.
Immunohistochemical and immunofluorescence stain-
ing results showed most cells positive for cytoplasmic
HMGB1 were also positive for NeuN. A small number
of cytoplasmic HMGB1-positive cells were found to be
microglia. Neurons seem to be susceptible after brain in-
jury and the main source of extracellular HMGB1. Actu-
ally, not only in the SAH model in vivo and in vitro, but
also in the ischemic brain, neurons seem to be the main
source of HMGB1 in the early stage of brain injury [10].
Early-released HMGB1 from neurons might be the
Figure 11 Conditioned medium from Hb-treated neurons
induced IL-1β in cultured mixed glial cells, which could be
inhibited by High-mobility group box 1 (HMGB1)-specific inhibitor.
Cultured mixed glial cells were arranged into three groups. In the
control group mixed glial cells were treated with control medium; in
the medium group mixed glial cells were treated with neuron
medium; in the medium + glycyrrhizic acid (GA) group, after mixed
glial cells were treated with neuron medium, a special inhibitor of
HMGB1 (GA) was added in the medium to silence the activity of
HMGB1. IL-1β was measured by real-time PCR. Bars represent the
mean ± standard error (n = 6), *P < 0.05 compared with the medium
group; #P < 0.01 compared with the control group.
Sun et al. Journal of Neuroinflammation 2014, 11:106 Page 14 of 16
http://www.jneuroinflammation.com/content/11/1/106important early upstream factor in the following inflam-
matory response after SAH. To better understand
whether neuron-derived HMGB1 could signal to mixed
glial cells, medium from neurons, which had been stim-
ulated by Hb, was used to culture the mixed glial cells
(see detailed information in Method and material). The
result demonstrates that HMGB1 released from neurons
could initiate the inflammatory response in mixed glial
cells. Thus, it could be supposed that HMGB1 released
from neurons might influence neighboring glial cells and
up-regulate the inflammatory factors, which could in
turn stimulate brain cells to release more HMGB1 with
an up-regulated mRNA level of HMGB1 [9]. This result
suggests further that HMGB1 might be an early up-
stream factor in inflammation after SAH. Myeloid differ-
entiation primary response protein 88 (downstream of
TLRs) and RAGE were also reported to be up-regulated
mainly in neurons after SAH [3,26]. Our previous study
in vitro showed addition of rHMGB1 could also increase
MyD88 expression in protein and mRNA levels in cul-
tured neurons with up-regulated inflammatory factors
[22]. According to these studies, it seems that relative
healthy neurons nearby could also be reactive cells for
extracellular HMGB1 as well as glial cells. A small num-
ber of microglia was observed to release HMGB1 in the
beginning. However, it was believed that more and more
microglia would start to secrete HMGB1 as time devel-
oped, which was observed in the late stage in a previous
study [13]. Interestingly, this phenomenon also exists inthe late stage of the ischemic brain [32]. HMGB1 released
from microglia might be responsible for the inflammation
in the late stage.
Addition of rHMGB1 up-regulated cleaved caspase 3,
a possible marker of apoptosis in the cortex, especially
in neurons (Figure 9). Extracellular rHMGB1 seemed
harmful for survival of brain cells. The explicit mechan-
ism is not yet clear. The inflammatory response induced
by rHMGB1 might be the possible reason. It is widely
believed that inflammation in the early stage contributes
to the brain injury and it has been confirmed that inhib-
ition of NF-κB and downstream inflammatory factors
confer protection in the early stage [2,8,24]. Increased
inflammatory factors, such as IL-1β and TNF-α, could
mediate cell apoptosis and cell damage [33,34]. Thus, it
was suspected that the rHMGB1 might accelerate brain
injury through up-regulated inflammation. How the
rHMGB1 in the subarachnoid space influenced the cor-
tex parenchymal cells is not yet clear. Maybe it shared a
similar process to the intraventricular injection of lipo-
polysaccharide [34] or the small molecule HMGB1 might
be able to easily infiltrate the pia mater because of its
small molecular weight.
Rodex modification of 106 cysteine in the HMGB1
molecule might be critical for its cytokine activity. Oxi-
dization of the cysteine at position 106 in HMGB1 could
suppress the pro-inflammtory activity [35,36]. However,
although together with ROS, HMGB1 retains its activity
during the inflammatory process in a glutamate-treated-
neurons model, oxygen-glucose deprivation model [10]
and an N-methyl-D-aspartic acid (NMDA)-treated model
[32]. Further research using tandem mass spectrometric
analysis indicated that the predominant form of HMGB1
during the inflammatory process is not oxidized. When
the inflammation was resolved, the form of HMGB1 was
oxidized [35]. As shown in Figure 11, although ROS could
be provided by hemoglobin, HMGB1 cytokine activity
still existed and triggered inflammation in glial cells.
Furthermore, ROS also damages cells itself and upregu-
lates HMGB1 release [37]. Thus oxidization could not
silence all the HMGB1 because the treatment target of
HMGB1 could alleviate the inflammatory response [38].
Early use of HMGB1 inhibitor, such as GA, might be a
good choice for stopping the harmful inflammatory
response.
Combining the research listed above, we could specu-
late that early-released HMGB1 from neurons after SAH
onset might trigger inflammation in neurons [22], and
glial cells nearby with their MyD88-level up-regulated
[3]. Increased levels of inflammatory factors might trigger
more cells to actively secrete HMGB1 [9]. Up-regulated
inflammation contributes to the BBB breakdown, brain
edema, cell apoptosis and death. Extracellular HMGB1
might be the early key mediator that mediates cross-talk
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damaged tissues [16].
The effects in clinic trials targeting a single signal in
the inflammatory pathway are not as good as expected
[39,40]. Inflammation is such a complex pathophysio-
logical process, that treatment simply targeting a single
molecule or receptor is difficult to determine. It is import-
ant to find out the source of the inflammatory response.
Our research points out that HMGB1 might be the early
key mediator in the process of SAH and a novel potential
target for treatment [41].
Summary
As mentioned above, HMGB1 is massively released from
neurons early after SAH onset. Passive and active releases
are involved in the translocation process. Extracellular
HMGB1 represented a pro-inflammatory role and con-
tributed to brain injury. HMGB1 might be the major up-
stream inflammatory mediator, which might be a potential
treatment target.
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